Kansas HB 2159: Providing for additional sources of revenue for the water program management fund and creating additional fees for the regulation of underground injection control wells.

Bill Text

As Further Amended by House Committee
As Amended by House Committee
Session of 2025
HOUSE BILL No. 2159
By Representatives Proctor and Hoheisel
1-30
AN ACT concerning law enforcement; relating to emergency opioid
antagonists; creating the emergency opioid antagonists assistance grant
fund to assist law enforcement agencies with purchasing emergency
opioid antagonists; maintaining immunity for law enforcement agencies
and officers for damages resulting from administering an emergency
opioid antagonist; removing law enforcement agencies and officers
from the state board of pharmacy's statewide opioid antagonist
protocol; amending K.S.A. 2024 Supp. 65-16,127 and repealing the
existing section.
Be it enacted by the Legislature of the State of Kansas:
New Section 1. (a) There is hereby established in the state treasury
the emergency opioid antagonists assistance grant fund, to be administered
by the attorney general. All moneys credited to the fund shall be for
providing assistance to law enforcement agencies across the state in
purchasing emergency opioid antagonists.
(2) All expenditures from the emergency opioid antagonists
assistance account grant fund shall be made in accordance with
appropriation acts upon warrants of the director of accounts and reports
issued pursuant to vouchers approved by the attorney general or the
attorney general's designee.
(c) The attorney general shall develop and implement the emergency
opioid antagonists assistance grant program with the goal of providing
assistance to law enforcement agencies across the state in purchasing
emergency opioid antagonists for law enforcement officers to carry while
such officers are on duty. Prioritization of emergency opioid antagonists
assistance grant fund moneys shall be given to small law enforcement
agencies. Only a law enforcement agency that has adopted a policy
requiring the administration of emergency opioid antagonists shall be
eligible to receive a grant pursuant to this subsection.
(d) On July 1, 2025, and on July 1 of each year thereafter, the director
of accounts and reports shall transfer $4,000,000 $500,000 from the state
general fund to the emergency opioid antagonist assistance grant fund.
Sec. 2. Section 1. K.S.A. 2024 Supp. 65-16,127 is hereby amended to
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

HB 2159—Fur. Am. by HC 2
read as follows: 65-16,127. (a) As used in this section:
(1) "Bystander" means a family member, friend, caregiver or other
person in a position to assist a person who the family member, friend,
caregiver or other person believes, in good faith, to be experiencing an
opioid overdose.
(2) "Emergency opioid antagonist" means any drug that inhibits the
effects of opioids and that is approved by the United States food and drug
administration for the treatment of an opioid overdose.
(3) (A) "First responder" includes any emergency medical service
provider, as defined by K.S.A. 65-6112, and amendments thereto, any law
enforcement officer, as defined by K.S.A. 22-2202, and amendments
thereto, any law enforcement officer, as defined by K.S.A. 22-2202, and
amendments thereto, and any actual member of any organized fire
department, whether regular or volunteer.
(B) "First responder" does not include any law enforcement officer,
as defined in K.S.A. 22-2202, and amendments thereto.
(4) (A) "First responder agency" includes, but is not limited to, any
law enforcement agency, law enforcement agency, fire department or
criminal forensic laboratory or criminal forensic laboratory of any city,
county or the state of Kansas.
(B) "First responder agency" does not include any law enforcement
agency.
(5) "Opioid antagonist protocol" means the protocol established by
the state board of pharmacy pursuant to subsection (b).
(6) "Opioid overdose" means an acute condition including, but not
limited to, extreme physical illness, decreased level of consciousness,
respiratory depression, coma, mania or death, resulting from the
consumption or use of an opioid or another substance with which an
opioid was combined, or that a layperson would reasonably believe to be
resulting from the consumption or use of an opioid or another substance
with which an opioid was combined, and for which medical assistance is
required.
(7) "Patient" means a person believed to be at risk of experiencing an
opioid overdose.
(8) "School nurse" means a professional nurse licensed by the board
of nursing and employed by a school district to perform nursing
procedures in a school setting.
(9) "Healthcare provider" means a physician licensed to practice
medicine and surgery by the state board of healing arts, a licensed dentist,
a mid-level practitioner as defined by K.S.A. 65-1626, and amendments
thereto, or any person authorized by law to prescribe medication.
(b) The state board of pharmacy shall issue a statewide opioid
antagonist protocol that establishes requirements for a licensed pharmacist
1
2
3
4
5
6
7
8
9